Welcome to CDC Stacks | Comparison of Prior Authorization and Prospective Audit with Feedback for Antimicrobial Stewardship - 30144 | CDC Public Access
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Comparison of Prior Authorization and Prospective Audit with Feedback for Antimicrobial Stewardship
Filetype[PDF - 2.27 MB]


Details:
  • Corporate Authors:
    for the Centers for Disease Control and Prevention Epicenter Program
  • Description:
    OBJECTIVE

    Although prior authorization and prospective audit with feedback are both effective antimicrobial stewardship program (ASP) strategies, the relative impact of these approaches remains unclear. We compared these core ASP strategies at an academic medical center.

    DESIGN

    Quasi-experimental study.

    METHODS

    We compared antimicrobial use during the 24 months before and after implementation of an ASP strategy change. The ASP used prior authorization alone during the preintervention period, June 2007 through May 2009. In June 2009, many antimicrobials were unrestricted and prospective audit was implemented for cefepime, piperacillin/tazobactam, and vancomycin, marking the start of the postintervention period, July 2009 through June 2011. All adult inpatients who received more than or equal to 1 dose of an antimicrobial were included. The primary end point was antimicrobial consumption in days of therapy per 1,000 patient-days (DOT/1,000-PD). Secondary end points included length of stay (LOS).

    RESULTS

    In total, 55,336 patients were included (29,660 preintervention and 25,676 postintervention). During the preintervention period, both total systemic antimicrobial use (−9.75 DOT/1,000-PD per month) and broad-spectrum anti-gram-negative antimicrobial use (−4.00 DOT/1,000-PD) declined. After the introduction of prospective audit with feedback, however, both total antimicrobial use (+9.65 DOT/1,000-PD per month; P < .001) and broad-spectrum anti-gram-negative antimicrobial use (+4.80 DOT/1,000-PD per month; P < .001) increased significantly. Use of cefepime and piperacillin/tazobactam both significantly increased after the intervention (P = .03). Hospital LOS and LOS after first antimicrobial dose also significantly increased after the intervention (P = .016 and .004, respectively).

    CONCLUSIONS

    Significant increases in antimicrobial consumption and LOS were observed after the change in ASP strategy.

  • Document Type:
  • Collection(s):
  • Funding:
    K24 AI080942/AI/NIAID NIH HHS/United States
    T32 GM075766/GM/NIGMS NIH HHS/United States
    U54-CK000163/CK/NCEZID CDC HHS/United States
    UL1 TR000003/TR/NCATS NIH HHS/United States
    UL1TR000003/TR/NCATS NIH HHS/United States
No Related Documents.
You May Also Like: